SolomonEpsteinMDFACP FRCP

PubMed

• 25 citations
  Emerging concepts in the epidemiology, pathophysiology, and clinical care of osteoporosis across the menopausal transition.
  Daria Lizneva, Tony Yuen, Li Sun, Se-Min Kim, Ihor Atabiekov, Lubna Bashir Munshi, Sol Epstein, Maria I. New, Mone Zaidi> ;Matrix Biology. 2018 May 5
• 48 citations
  A Unified Pathophysiological Construct of Diabetes and its Complications
  Stanley Schwartz, Solomon Epstein, Barbara E. Corkey, Struan F.A. Grant, James R. Gavin, Richard B. Aguilar, Mary E. Herman> ;Trends in Endocrinology and Metabolism. 2017 Sep 1
• Corrigendum to "The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes".
  Nicola Napoli, Rocky Strollo, Angela Paladini, Silvia Briganti, Paolo Pozzilli, Sol Epstein> ;International Journal of Endocrinology. 2017 Jul 2
• Response to Comment on Schwartz et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification ...
  Stanley Schwartz, Solomon Epstein, Barbara E. Corkey, Struan F.A. Grant, James R. Gavin, Richard B. Aguilar> ;Diabetes Care. 2016 Aug 1
• 174 citations
  The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
  Stanley Schwartz, Solomon Epstein, Barbara E. Corkey, Struan F.A. Grant, James R. Gavin, Richard B. Aguilar> ;Diabetes Care. 2016 Feb 1
• 12 citations
  Questioning the association between bisphosphonates and atypical femoral fractures.
  Michael Pazianas, Se-Min Kim, Tony Yuen, Li Sun, Sol Epstein, Mone Zaidi> ;Annals of the New York Academy of Sciences. 2015 Jan 1
• 32 citations
  Secondary osteoporosis: Pathophysiology & diagnosis
  Gregory R. Emkey, Sol Epstein> ;Best Practice & Research. Clinical Endocrinology & Metabolism. 2014 Dec 1
• 65 citations
  The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes
  Nicola Napoli, Rocky Strollo, Angela Paladini, Silvia Briganti, Paolo Pozzilli, Sol Epstein> ;International Journal of Endocrinology. 2014 Jul 16
• 28 citations
  The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.
  Emily J. Gallagher, Hui Sun, Caroline Kornhauser, Aviva Tobin-Hess, Sol Epstein, Shoshana Yakar, Derek LeRoith> ;Diabetes/metabolism Research and Reviews. 2014 Mar 1
• 264 citations
  Quality of life in sarcopenia and frailty.
  René Rizzoli, Jean-Yves Reginster, Jean-François Arnal, Ivan Bautmans, Charlotte Beaudart, Heike A. Bischoff-Ferrari, Emmanuel Biver, Steven Boonen, Maria-Luisa Brandi...> ;Calcified Tissue International. 2013 Jul 5
• Rheumatic Disease Clinics of North America. Vitamin D. Preface.
  Sol Epstein> ;Rheumatic Diseases Clinics of North America. 2012 Feb 1
• 6 citations
  Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg
  S. Epstein, M. Jeglitsch, Eugene V. McCloskey> ;Current Medical Research and Opinion. 2009 Nov 16
• 62 citations
  Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis
  Yuki Kawashima, J. Christopher Fritton, Shoshana Yakar, Sol Epstein, Mitchell B. Schaffler, Karl J. Jepsen, Derek LeRoith> ;Bone. 2009 Apr 1
• 33 citations
  Diabetes and fragility fractures — A burgeoning epidemic?
  Sol Epstein, Derek LeRoith> ;Bone. 2008 Jul 1
• 57 citations
  Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
  Paul D. Miller, Sol Epstein, Farhad Sedarati, Jean-Yves Reginster> ;Current Medical Research and Opinion. 2008 Jan 1
• 42 citations
  Is cortical bone hip? What determines cortical bone properties?
  Sol Epstein> ;Bone. 2007 Jul 1
• 3 citations
  Is treatment of early postmenopausal women with bisphosphonates justified
  S. Epstein> ;International Journal of Clinical Practice. 2007 Jun 1
• Modern advances in the understanding of bone structure.
  Sol Epstein> ;Bone. 2007 Jul 1
• 17 citations
  Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety
  Sol Epstein, Pierre D. Delmas, Ronald Emkey, K. Wilson, Valerie Hiltbrunner, R. C. Schimmer> ;Maturitas. 2006 Apr 20
• 2 citations
  Ibandronate treatment for osteoporosis: Rationale, preclinical and clinical development of extended dosing regimens
  Solomon Epstein> ;Current Osteoporosis Reports. 2006 Mar 1
• 72 citations
  Update of current therapeutic options for the treatment of postmenopausal osteoporosis
  Solomon Epstein> ;Clinical Therapeutics. 2006 Feb 1
• 18 citations
  Biological properties and mechanism of action of ibandronate: Application to the treatment of osteoporosis
  S. Epstein, Mone Zaidi> ;Bone. 2005 Oct 1
• 50 citations
  The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy
  Solomon Epstein> ;Mayo Clinic Proceedings. 2005 Mar 1
• 36 citations
  Disintegration/dissolution profiles of copies of Fosamax (alendronate).
  Solomon Epstein, Byron Cryer, S. Ragi, Jose R. Zanchetta, J. Walliser, J. Chow, M. A. Johnson, A. E. Leyes> ;Current Medical Research and Opinion. 2003 Jan 1
• 63 citations
  Disorders Associated With Acute Rapid and Severe Bone Loss
  Solomon Epstein, Angela M. Inzerillo, John Caminis, Mone Zaidi> ;Journal of Bone and Mineral Research. 2003 Dec 1
• Join now to see all